RMC-4627

RMC-4627 is a bi-steric, small molecule inhibitor that selectively targets mTOR complex 1 (mTORC1). It is composed of a rapamycin core covalently linked to a PP242-derived active site inhibitor via an ether bond and a Peg8 linker. The drug demonstrates potent and selective inhibition of mTORC1 signaling, achieving strong suppression of downstream targets such as p-4EBP1 and p-S6K at low nanomolar concentrations, while sparing mTORC2. RMC-4627 induces apoptotic cell death in tumor models, suppresses cell cycle progression, exhibits durable inhibition even after washout, and enhances the cytotoxicity of dasatinib in preclinical models of B-cell acute lymphoblastic leukemia (B-ALL). Its selectivity and prolonged action make it a promising research tool for studying mTORC1 biology and a possible future component of targeted leukemia therapies[1][3][5][6][7].